Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 192

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs

Open access
Xu, Qinghua, Zhou, Fei, Liu, Hui, Jiang, Tao, Li, Xuefei, Xu, Yaping, Zhou, Caicun · 2018 · Journal of Thoracic Oncology

Abstract

Introduction: The aim of the current study was to investigate whether consolidative local ablative therapy (LAT) can improve the survival of patients with stage IV EGFR‐mutant NSCLC who have oligometastatic disease treated with first‐line EGFR–tyrosine kinase inhibitor (TKI) therapy. Methods: Patients with stage IV EGFR‐mutant NSCLC and no more than five metastases within 2 months of diagnosis were identified. All patients were treated with first‐line EGFR‐TKIs. Consolidative LAT included radiotherapy, surgery, or both. Overall survival (OS) and progression‐free survival (PFS) were estimated by Kaplan‐Meier curves. Results: From October 2010 to May 2016, 145 patients were enrolled, including 51 (35.2%) who received consolidative LAT to all oligometastatic sites (all‐LAT group), 55 (37.9%) who received consolidative LAT to either primary tumor or oligometastatic sites (part‐LAT group), and 39 (26.9%) who did not receive any consolidative LAT (non‐LAT group). The median PFS in all‐LAT, part‐LAT, and non‐LAT groups were 20.6, 15.6, and 13.9 months, respectively (p < 0.001). The median OS in all‐LAT, part‐LAT, and non‐LAT groups were 40.9, 34.1, and 30.8 months, respectively (p < 0.001). The difference was statistically significant between the all‐LAT group and part‐LAT or non‐LAT group but was not between the part‐LAT and non‐LAT group. The median OS was significantly improved with consolidative LAT for primary tumor (40.5 versus 31.5 months, p < 0.001), brain metastases (38.2 versus 29.2 months, p = 0.002), and adrenal metastases (37.1 versus 29.2 months, p = 0.032). Adverse events (grade ≥ 3) due to radiotherapy included pneumonitis (7.7%) and esophagitis (16.9%). Conclusions: The current study showed that consolidative LAT to all metastatic sites was a feasible option for patients with EGFR‐mutant oligometastatic NSCLC during first‐line EGFR‐TKI treatment, with significantly improved PFS and OS compared with consolidative LAT to partial sites or observation alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2018.05.019

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 192

Metadata

Authors
Xu, Q., Zhou, F., Liu, H., Jiang, T., Li, X., Xu, Y., & Zhou, C.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2018-09
Volume
13
Issue
9
Pages
1383-1392
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2806810471
Cited by
192
References
7
FWCI
14.03
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.